| 摘要 |
<p>Gene therapy-based treatment of type-2 diabetes, obesity, and related conditions by in vivo expression of glucagon-like peptide 1 (GLP-1), and/or glucose-dependent insulinotropic peptide (GIP). The treatment may be combined with concurrent administraton of dipeptidyl peptidase IV (DPP-IV) inhibitors.</p> |
